Merck's Enflonsia vaccine for respiratory syncytial virus won approval from the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices.

U.S. Health Secretary Robert F. Kennedy Jr.'s newly revamped vaccine advisory panel voted on Thursday to recommend use of Merck's recently approved RSV antibody drug for infants 8 months or younger whose mothers did not receive a preventive shot during pregnancy.

RFK Jr.’s vaccine panel endorsed Merck’s RSV shot for babies, easing fears that his stance might delay rollout.